E-submission
Search
- Page Path
- HOME > Search
Brief Case Report
- Liquid-Based Cytology Features of Papillary Squamotransitional Cell Carcinoma of the Uterine Cervix
- Yangkyu Lee, Younghwa Choi, Kiryang Lee, Youngeun Lee, Hyojin Kim, Ji-Young Choe, Hye Seung Lee, Yong Beom Kim, Haeryoung Kim
- J Pathol Transl Med. 2019;53(5):341-344. Published online June 24, 2019
- DOI: https://doi.org/10.4132/jptm.2019.06.05
- 4,475 View
- 102 Download
- 1 Web of Science
- 1 Crossref
Original Articles
- Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma
- Ji-Young Choe, Ji Yun Yun, Soo-Jeong Nam, Ji Eun Kim
- Korean J Pathol. 2012;46(6):515-522. Published online December 26, 2012
- DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.6.515
- 6,379 View
- 44 Download
- 18 Crossref
-
Abstract
PDF Background Activation of the c-Met pathway is involved in cancer progression and the prognosis. We aimed to identify any association of c-Met protein expression with a number of clinicopathologic variables including infection of human papillomavirus and Epstein-Barr virus (EBV) in head and neck carcinomas (HNCa).
Methods Eighty-two cases were enrolled in this study. Expression of c-Met and p16 was investigated immunohistochemically. EBV was detected by
in situ hybridization and amplification of thec-Met gene by fluorescencein situ hybridization.Results The c-Met protein was expressed in 41.5% (34/82), and gene amplification was found in 1.4% (1/71). High expression of c-Met was associated with the primary location of the tumor; the hypopharynx showed the highest expression, followed by the oral cavity, larynx, and nasal cavity. Squamous cell carcinoma expressed c-Met more frequently than undifferentiated carcinoma. Also, p16 immunoreactivity or EBV infection was associated with the tumor location and well-differentiated histologic type, but were not linked to c-Met expression. The patients with positive c-Met expression showed frequent lymph node metastasis.
Conclusions Activation of the c-Met pathway might be involved in a subset of HNCa. Cases showing positive c-Met expression should be carefully monitored because of the high probability of lymph node metastasis.
-
Citations
Citations to this article as recorded by
- c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy
Chakrabhavi Dhananjaya Mohan, Muthu K Shanmugam, Siddegowda Gopalapura Shivanne Gowda, Arunachalam Chinnathambi, Kanchugarakoppal S. Rangappa, Gautam Sethi
Phytomedicine.2024; 128: 155379. CrossRef - Nadir paranazal sinüs kanserlerinde yeni tanımlanan reseptör tirozin kinaz mutasyonları ve potansiyel fonksiyonel etkileri
Bakiye GÖKER BAGCA, Sercan GÖDE, Göksel TURHAL, Neslihan Pınar ÖZATEŞ, Ali VERAL, Cumhur GÜNDÜZ, Çığır Biray AVCI
Ege Tıp Dergisi.2023; 62(1): 139. CrossRef - The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target
Antonio Faiella, Ferdinando Riccardi, Giacomo Cartenì, Martina Chiurazzi, Livia Onofrio, Rengyun Liu
Journal of Oncology.2022; 2022: 1. CrossRef - NK4 Regulates Laryngeal Squamous Cell Carcinoma Cell Properties and Inhibits Tumorigenicity by Modulating the DKK1/Wnt/β-Catenin Axis
Shoukai Zhang, Hulai Wei, Xiaoqin Ha, Yueyu Zhang, Yufen Guo
Frontiers in Oncology.2021;[Epub] CrossRef - Epstein-Barr Virus-Associated Carcinoma of the Larynx: A Systematic Review with Meta-Analysis
Marcos Antonio Pereira de Lima, Álife Diêgo Lima Silva, Antônio Carlos Silva do Nascimento Filho, Thiago Lima Cordeiro, João Pedro de Souza Bezerra, Maria Aline Barroso Rocha, Sally de França Lacerda Pinheiro, Roberto Flávio Fontenelle Pinheiro Junior, Ma
Pathogens.2021; 10(11): 1429. CrossRef - The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma
Alexandre A. B. A. da Costa, Felipe D’Almeida Costa, Daniel Vilarim Araújo, Marcos Pedro Guedes Camandaroba, Victor Hugo Fonseca de Jesus, Audrey Oliveira, Ana Caroline Fonseca Alves, Carlos Stecca, Larissa Machado, Andrea Cruz Feraz de Oliveira, Thiago B
Medical Oncology.2019;[Epub] CrossRef - Role of c‐Met expression on prognosis of head and neck cancer: A literature review and meta‐analysis
Lei Li, Zhijun Sun, Xin Huang, Xiao Li, Lihua Sun, Lei Zhang, Xiaodan Zhang, Longwei Ye, Jie Yuan, Limin Mao, Guolin Li
Head & Neck.2019; 41(6): 1999. CrossRef - MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation
Lisa Pei Chu, Debra Franck, Christine A. Parachoniak, Jeffrey P. Gregg, Michael G. Moore, D. Gregory Farwell, Shyam Rao, Andreas M. Heilmann, Rachel L. Erlich, Jeffrey S. Ross, Vincent A. Miller, Siraj Ali, Jonathan W. Riess
The Oncologist.2019; 24(10): 1305. CrossRef - Understanding c-MET signalling in squamous cell carcinoma of the head & neck
P. Szturz, E. Raymond, C. Abitbol, S. Albert, A. de Gramont, S. Faivre
Critical Reviews in Oncology/Hematology.2017; 111: 39. CrossRef - Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data
Petr Szturz, Marie Budíková, Jan B. Vermorken, Ivana Horová, Břetislav Gál, Eric Raymond, Armand de Gramont, Sandrine Faivre
Oral Oncology.2017; 74: 68. CrossRef - Activated HGF-c-Met Axis in Head and Neck Cancer
Levi Arnold, Jonathan Enders, Sufi Thomas
Cancers.2017; 9(12): 169. CrossRef - Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review
Jung Han Kim, Bum Jun Kim, Hyeong Su Kim
Oncotarget.2017; 8(68): 113120. CrossRef - High expression of c‑Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma
Mei Jiang, Hui Zhang, He Xiao, Zhimin Zhang, Dan Que, Jia Luo, Jian Li, Bijing Mao, Yuanyuan Chen, Meilin Lan, Ge Wang, Hualiang Xiao
Oncology Letters.2017;[Epub] CrossRef - Profiling of cMET and HER Family Receptor Expression in Pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies
Alexander Muckenhuber, Galina Babitzki, Marlene Thomas, Gabriele Hölzlwimmer, Magdalena Zajac, Moritz Jesinghaus, Frank Bergmann, Jens Werner, Albrecht Stenzinger, Wilko Weichert
Pancreas.2016; 45(8): 1167. CrossRef - Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma
Maria J. De Herdt, Stefan M. Willems, Berdine van der Steen, Rob Noorlag, Esther I. Verhoef, Geert J.L.H. van Leenders, Robert J.J. van Es, Senada Koljenović, Robert J. Baatenburg de Jong, Leendert H.J. Looijenga
Oncotarget.2016; 7(11): 13167. CrossRef - Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer
Lluís Nisa, Daniel Matthias Aebersold, Roland Giger, Yitzhak Zimmer, Michaela Medová
Pharmacology & Therapeutics.2014; 143(3): 337. CrossRef - Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus–negative tonsillar squamous cell carcinoma and their prognostic significances
Mi Jung Kwon, Dong Hoon Kim, Hye-Rim Park, Hyung Sik Shin, Ji Hyun Kwon, Dong Jin Lee, Jin Hwan Kim, Seong Jin Cho, Eun Sook Nam
Human Pathology.2014; 45(7): 1327. CrossRef - Distinct c-Met activation mechanisms induce cell rounding or invasion through pathways involving integrins, RhoA and HIP1
Anja Mai, Ghaffar Muharram, Rachel Barrow-McGee, Habib Baghirov, Juha Rantala, Stéphanie Kermorgant, Johanna Ivaska
Journal of Cell Science.2014; 127(9): 1938. CrossRef
- c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy
- Cyclooxygenase-2 Expression and Its Prognostic Significance in Clear Cell Renal Cell Carcinoma
- Ji Won Lee, Jeong Hwan Park, Ja Hee Suh, Kyung Han Nam, Ji-Young Choe, Hae Yoen Jung, Ji Yoen Chae, Kyung Chul Moon
- Korean J Pathol. 2012;46(3):237-245. Published online June 22, 2012
- DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.3.237
- 7,380 View
- 34 Download
- 16 Crossref
-
Abstract
PDF
Background The prognostic value of cyclooxygenase-2 (COX-2) in human renal cell carcinoma (RCC) remains unclear. The purposes of this study are to elucidate the clinical significance of COX-2 in clear cell RCC (CCRCC) and to assess the treatment effect of COX-2 inhibition on CCRCC cell lines.
Methods Using tumor samples obtained from 137 patients who had undergone nephrectomy at Seoul National University Hospital, we evaluated COX-2 expression on immunohistochemistry. Moreover, we performed the cell proliferation assay using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-2H tetrazolium bromide (MTT) and cell invasion assay. Thus, we evaluated the effect of meloxicam, an inhibitor of COX-2, in two human CCRCC cell lines.
Results Cancer-specific survival (p=0.038) and progression-free survival (p=0.031) were shorter in the COX-2 high expression group. A multivariate logistic regression model showed that COX-2 expression was an independent risk factor for pTNM stage and Fuhrman nuclear grade. The MTT assay revealed that COX-2 inhibition led to the suppression of the proliferation of CCRCC cell lines. Moreover, it also reduced their invasion capacity.
Conclusions This study postulates that COX-2 is a poor prognostic indicator in human CCRCC, suggesting that COX-2 inhibition can be a potential therapy in CCRCC.
-
Citations
Citations to this article as recorded by- Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition
Xiao-Jun Li, Ping Suo, Yan-Ni Wang, Liang Zou, Xiao-Li Nie, Ying-Yong Zhao, Hua Miao
Frontiers in Pharmacology.2024;[Epub] CrossRef - The tumor microenvironment and immune targeting therapy in pediatric renal tumors
Amy B. Hont, Benoit Dumont, Kathryn S. Sutton, John Anderson, Alex Kentsis, Jarno Drost, Andrew L. Hong, Arnauld Verschuur
Pediatric Blood & Cancer.2023;[Epub] CrossRef - Free-fatty acid receptor-1 (FFA1/GPR40) promotes papillary RCC proliferation and tumor growth via Src/PI3K/AKT/NF-κB but suppresses migration by inhibition of EGFR, ERK1/2, STAT3 and EMT
Priyanka F. Karmokar, Nader H. Moniri
Cancer Cell International.2023;[Epub] CrossRef - Flavonoids derived from Anemarrhenae Rhizoma ameliorate inflammation of benign prostatic hyperplasia via modulating COX/LOX pathways
Xiaotong Cao, Ying Shang, Weigui Kong, Shuqing Jiang, Jun Liao, Ronghua Dai
Journal of Ethnopharmacology.2022; 284: 114740. CrossRef - Kirenol, darutoside and hesperidin contribute to the anti-inflammatory and analgesic activities of Siegesbeckia pubescens makino by inhibiting COX-2 expression and inflammatory cell infiltration
Yu-Sang Li, Jian Zhang, Gui-Hua Tian, Hong-Cai Shang, He-Bin Tang
Journal of Ethnopharmacology.2021; 268: 113547. CrossRef - Differential expression of cyclooxygenase-2 and cyclin D1 in salivary gland tumors
Jefferson da Rocha Tenório, Leorik Pereira da Silva, Marília Gabriela de Aguiar Xavier, Thalita Santana, George João Ferreira do Nascimento, Ana Paula Veras Sobral
European Archives of Oto-Rhino-Laryngology.2018; 275(9): 2341. CrossRef - Retrospective evaluation of COX‐2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy
S. Carvalho, A. L. Stoll, S. L. Priestnall, A. Suarez‐Bonnet, K. Rassnick, S. Lynch, I. Schoepper, G. Romanelli, P. Buracco, M. Atherton, E. M. de Merlo, A. Lara‐Garcia
Veterinary and Comparative Oncology.2017; 15(4): 1280. CrossRef - Functional PTGS2 polymorphism-based models as novel predictive markers in metastatic renal cell carcinoma patients receiving first-line sunitinib
Arancha Cebrián, Teresa Gómez del Pulgar, María José Méndez-Vidal, María Luisa Gonzálvez, Nuria Lainez, Daniel Castellano, Iciar García-Carbonero, Emilio Esteban, Maria Isabel Sáez, Rosa Villatoro, Cristina Suárez, Alfredo Carrato, Javier Munárriz-Ferránd
Scientific Reports.2017;[Epub] CrossRef - COX-2 expression in ovarian cancer: an updated meta-analysis
Haiming Sun, Xuelong Zhang, Donglin Sun, Xueyuan Jia, Lidan Xu, Yuandong Qiao, Yan Jin
Oncotarget.2017; 8(50): 88152. CrossRef - COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis
Hedieh Moradi Tabriz, Marzieh Mirzaalizadeh, Shahram Gooran, Farzaneh Niki, Maryam Jabri
Asian Pacific Journal of Cancer Prevention.2016; 17(2): 535. CrossRef - Lipidomic Signatures and Associated Transcriptomic Profiles of Clear Cell Renal Cell Carcinoma
Kosuke Saito, Eri Arai, Keiko Maekawa, Masaki Ishikawa, Hiroyuki Fujimoto, Ryo Taguchi, Kenji Matsumoto, Yae Kanai, Yoshiro Saito
Scientific Reports.2016;[Epub] CrossRef - Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma
Łukasz Kuźbicki, Dariusz Lange, Agata Stanek-Widera, Barbara W. Chwirot
Melanoma Research.2016; 26(5): 448. CrossRef - New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis
Honor J. Hugo, C. Saunders, R. G. Ramsay, E. W. Thompson
Journal of Mammary Gland Biology and Neoplasia.2015; 20(3-4): 109. CrossRef - The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy
Katarzyna Kaminska, Cezary Szczylik, Fei Lian, Anna M Czarnecka
Future Oncology.2014; 10(14): 2177. CrossRef - Genomics and epigenomics of clear cell renal cell carcinoma: Recent developments and potential applications
Małgorzata Rydzanicz, Tomasz Wrzesiński, Hans A.R. Bluyssen, Joanna Wesoły
Cancer Letters.2013; 341(2): 111. CrossRef - Quantitative Assessment of the Association of COX-2 (Cyclooxygenase-2) Immunoexpression with Prognosis in Human Osteosarcoma: A Meta-Analysis
Zhe Wang, Maolin He, Zengming Xiao, Hao Wu, Yang Wu, Dominique Heymann
PLoS ONE.2013; 8(12): e82907. CrossRef
- Arachidonic acid metabolism as a therapeutic target in AKI-to-CKD transition
First
Prev
